key: cord-0926651-xb154d6x
authors: Olsen, Randall J.; Christensen, Paul A.; Long, S. Wesley; Subedi, Sishir; Hodjat, Parsa; Olson, Robert; Nguyen, Marcus; Davis, James J.; Yerramilli, Prasanti; Saavedra, Matthew Ojeda; Pruitt, Layne; Reppond, Kristina; Shyer, Madison N.; Cambric, Jessica; Gadd, Ryan; Thakur, Rashi M.; Batajoo, Akanksha; Finkelstein, Ilya J.; Gollihar, Jimmy; Musser, James M.
title: Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences
date: 2021-07-23
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.07.002
sha: 13ba0ea949987f719e570bb728b8096e96d8a26d
doc_id: 926651
cord_uid: xb154d6x

Certain genetic variants of SARS-CoV-2 are of substantial concern because they may be more transmissible or detrimentally alter the pandemic course and disease features in individual patients. We report SARS-CoV-2 genome sequences from 12,476 patients in the Houston Methodist healthcare system diagnosed from January 1 through May 31, 2021. Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63%-90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly higher hospitalization rate. Other variants (e.g., B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1) also increased rapidly, although the magnitude was less than B.1.1.7. We identified 22 patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants; these patients had a high rate of hospitalization. Breakthrough cases (n=207) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many that are not currently designated variants of interest or concern. In the aggregate, our study delineates the trajectory of SARS-CoV-2 variants circulating in a major metropolitan area, documents B.1.1.7 as the major cause of new cases in Houston, and heralds the arrival of B.1.617 variants in the metroplex.

There was no difference between these two groups in hospital length of stay or mortality. Eleven of the 3,276 B.1.1.7 genomes (0.3%) had an E484K change in spike protein that reduces binding by some neutralizing antibodies. Unexpectedly, we found five cases of B. 1 

Specimens were obtained from registered patients at Houston Methodist hospitals, associated facilities (e.g., urgent care centers), and institutions in the Houston metropolitan region that use 

Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital using assays granted Emergency Use Authorization (EUA) from the FDA (https://www.fda.gov/medicaldevices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests, last accessed June 7, 2021). As a hedge against supply chain strictures, multiple molecular testing platforms were used, including the COVID-19 test or RP2.1 test with BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system, and the SARS-CoV-2 assay using Abbott Alinity m instruments.

The great majority of tests were performed on material obtained from nasopharyngeal swabs immersed in universal transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar J o u r n a l P r e -p r o o f lavage fluid, or sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen collection methods were used (https://vimeo.com/396996468/2228335d56, last accessed June 7, 2021 

Metropolitan Houston has experienced three distinct epidemiologic peaks of COVID-19 ( Figure   1 ). The timing and shape of the epidemiologic curve for Houston Methodist patients mirrors the J o u r n a l P r e -p r o o f curve for the metropolitan region (https://covid-harriscounty.hub.arcgis.com/pages/cumulativedata, last accessed June 7, 2021). The third wave of COVID-19 started in approximately early November, following a prolonged disease trough occurring after the second wave (Figure 1) .

We studied 12,476 patients from January 1, 2021 through May 31, 2021, a period during which most of the VOIs and VOCs were initially identified in Houston, and several of them increased substantially ( Table 1, Figures 2, 3 and 4) .

The median age of the patients studied was 52.5 years, and 53% were female; 6,033 (48.4%) patients required hospitalization. The ethnic distribution of the patients ( Table 1) broadly reflects metropolitan Houston, which has a majority-minority population composition.

Median length of stay was (5.2 days), and the 28-day mortality rate was 4.7%.

The CDC has identified nine VOIs (B. (Figures 2, 3 and 4) .

In the last half of May, depending on the specific day, the B. (considered to be a proxy for higher virus loads) on initial diagnosis 9, 17 . Most authorities think that higher virus load in the upper respiratory tract is related to enhanced ability to spread and infect others, although there are many factors that contribute to virus transmission and disease.

We first tested the hypothesis that specimens from patients with B. 

Amino acid replacements at position E484 in spike protein have been of considerable research and public health interest, in part because they can decrease the efficacy of SARS-CoV-2 therapeutic antibodies and vaccine-or infection-induced adaptive immunity. We identified 363 samples with changes at E484 (E484K, n = 353; E484Q, n = 9; and E484D, n = 1) that occurred in many genetically diverse SARS-CoV-2 lineages, some of which have not shared a recent common ancestor. For example, we found the E484K polymorphism in samples from 69 patients reported that E484Q reduced viral neutralization for some plasma samples.

The N440K amino acid change in spike protein has recently been of interest because samples with this polymorphism have been reported to cause widespread COVID-19 in some states in India, increase viral titer in vitro, and have been associated with resistance to some candidate monoclonal antibody therapies. 58, 59 We identified 18 patients with this N440K replacement, and ten patients had the identical combination of spike amino acid replacements: L18R, T95I, R158S, N440K, D614G, P681H, A688V, S735A, and T1027I. Two additional patients had SARS-CoV-2 of this same spike protein genotype with an additional T376I amino acid replacement. Pangolin categorized these strains as B.1. These 18 individuals were from 14 different zip codes dispersed throughout five counties in metropolitan Houston (data not shown).

Ten of the 18 patients required hospitalization, and all were subsequently discharged. [63] [64] [65] The contributors to vaccine breakthroughs are not fully understood, but there is concern that genetic variants of SARS-CoV-2 may play an outsized role, especially those with structural changes in spike protein that can alter immunologic characteristics. Consistent with this idea, McEwen et al. 65 recently reported that all 20 vaccine breakthrough cases identified at the University of Washington were caused by VOCs. In contrast, a nationwide study found that 64% of breakthrough cases were caused by VOCs, although genome data were available from only 5% of reported cases included in the study 64 .

To test the hypothesis that VOCs and VOIs were overrepresented among postvaccination breakthrough infections among our COVID-19 cases, we examined metadata available for the 12,476 patients reported here. We identified 224 patients who met the criteria of vaccine breakthrough (i.e., infection occurring greater than 14 days after full vaccination was completed). SARS-CoV-2 genome sequence data were obtained for 207 cases ( Table 1) . Of these 207 patients, 72 (34.8%) required hospitalization. The 207 patients were infected with a heterogeneous array of variants, only some of which were VOIs or VOCs (Figure 8) . In the aggregate, there was a significant increase in VOIs or VOCs among the breakthrough cases (p < 0.001) ( Table 1) . Importantly, the infecting viruses generally reflected the spectrum of SARS-CoV-2 variants circulating in the Houston metropolitan region during the time of diagnosis of the vaccine breakthrough case. For example, in January and February 2021 many diverse variants were causing disease in the metroplex, and reflecting that fact, the viruses causing breakthrough cases were genetically heterogeneous (Figure 8) . Similarly, as the B.1.1.7 VOC rose to prominence in Houston in March, April, and May, it caused the great majority of vaccine J o u r n a l P r e -p r o o f breakthrough cases (Figure 8) . Of note, five breakthrough cases in April and May were caused by VOC P.1; this variant was also increasing in disease frequency during this period (Figures 2,   3 and 4 ).

We analyzed the molecular population genomics of SARS-CoV-2 occurring in metropolitan Houston, Texas, with a focus on infections occurring early in 2021, from January 1 through May 31. Our study was based on genome sequences from 12,476 ethnically, socioeconomically, and geographically diverse patients distributed throughout the metropolitan area. We discovered that Southeast Asia, and several areas of the U.K. [43] [44] [45] A key finding from our study was the very rapid growth trajectory of VOC B.1.1.7 in metropolitan Houston, an area with a population size of approximately 7 million. Several investigators have reported previously that patients infected with the B.1.1.7 VOC have significantly lower Ct values on initial diagnosis, but this has not been a universal finding. 11, [66] [67] [68] [69] [70] [71] In the absence of quantitative virus cultures, the Ct value is viewed by many as a convenient proxy for virus load. We found a significantly decreased Ct value in nasopharyngeal swabs taken J o u r n a l P r e -p r o o f from B.1.1.7 patients compared to non-B.1.1.7 patients (Table 1, Figure 7) , a result consistent with previous reports. 11 cases in our metropolitan region (Figure 1) . Although the precise cause of these seemingly disparate trends is unknown, we hypothesize that a relatively successful early vaccination campaign in the region coupled with heightened public awareness and concern about variants contributed to the decreasing case rate, whereas the increase in percent of cases caused by B.1.1.7 is attributed to the capacity of this variant to transmit more rapidly than other variants.

We cannot rule out a contribution of a small but significant ability of B.1.1.7 to evade immunity induced by either natural infection or vaccination, and our data are fully consistent with this idea ( Table 1) . In this regard, data have been published showing that B.1.1.7 differs in some immunologic characteristics compared to "wild-type" SARS-CoV-2. [75] [76] [77] [78] [79] [80] [81] [82] SARS-CoV-2 variants with the E484K amino acid replacement are of particular concern in many areas, including Brazil, South Africa, and India (https://www.cidrap.umn.edu/newsperspective/2021/02/pfizer-moderna-vaccines-may-be-less-effective-against-b1351-variant, last accessed: May 17, 2021) . Consistent with other studies, we identified the E484K change in several genetically distinct lineages of the virus, a finding likely due to convergent evolution, as noted previously by others. 39 The first Houston Methodist patient with the variant R.1 was identified in mid-December 2020, and its prevalence increased during the study period (Figures 2, 3 and 4) . Interestingly, for unknown reasons, its prevalence plateaued by early April (Figures 2, 3 and 4) .

We studied 207 symptomatic patients documented to be fully immunized and who had a specimen taken for diagnosis greater than 14 days after receiving their second dose of either the Pfizer (n = 181 patients, 87%) or Moderna (n = 26 patients, 13%) mRNA SARS-CoV-2 vaccine.

Because we are sequencing the virus genomes causing the vast majority of Houston Methodist Hospital cases (93%), we discovered that these vaccine breakthrough cases were caused by many diverse SARS-CoV-2 genotypes, including VOIs, VOCs, and many variants not assigned to either of these categories (Figure 8) . Our results are similar to those reported by Birhane et al. 64 but contrast with those reported recently by McEwen et al. 65 who found that all 20 breakthrough cases were caused by VOCs. Although we found the B. identified in the study, including VOIs, VOCs, and variant R.1. S1-NTD, S1 domainaminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a modified version of one presented previously 10 , with permission from Elsevier. nomenclature. S1-NTD, S1 domain-aminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a modified version of one presented previously 10 , with permission from Elsevier. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

China Novel Coronavirus I, Research T: A Novel Coronavirus from Patients with Pneumonia in China

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

A new coronavirus associated with human respiratory disease in China

Coronaviridae Study Group of the International Committee on Taxonomy of V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A novel coronavirus outbreak of global health concern

Country-level factors associated with the early spread of COVID-19 cases at 5, 10 and 15 days since the onset

Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area

Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern

Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in Houston, TX, revealed by 8,857 genome sequences

Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing

Unexpected Abundance of Clonal Group 307

Absence of patient-to-patient intrahospital transmission of Staphylococcus aureus as determined by whole-genome sequencing

Rapidly progressive, fatal, inhalation anthrax-like infection in a human: case report, pathogen genome sequencing, pathology, and coordinated response

Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences

Integrated analysis of population genomics, transcriptomics and virulence provides novel insights into Streptococcus pyogenes pathogenesis

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Spike mutation D614G alters SARS-CoV-2 fitness

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

SARS-CoV-2 spikeprotein D614G mutation increases virion spike density and infectivity

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2

Public health actions to control new SARS-CoV-2 variants

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

SARS-CoV-2 Viral Variants-Tackling a Moving Target

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Grubaugh ND: Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States

Analysis of severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch databases

Estimating the increased transmissibility of the B.1.1.7 strain over previously circulating strains in England using frequencies of GISAID sequences and the distribution of serial intervals

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro

Emergence and rapid spread of a new severe acute respiratory syndrome-related J o u r n a l P r e -p r o o f coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant

SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies

Danon L: Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England

Genomic reconstruction of the SARS-CoV-2 epidemic J o u r n a l P r e

Lineage Variant in a Skilled Nursing Facility After Vaccination Program -Kentucky

Household transmission of SARS-CoV-2 R.1 lineage with spike E484K mutation in Japan

Introductions and evolutions of SARS-CoV-2 strains in Japan

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Harinivas Harshan K: N440K variant of SARS-CoV-2 has Higher Infectious Fitness

Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Roychoudhury P: Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State

Traces of human migrations in Helicobacter pylori populations

Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein

Increased infections, but not viral burden, with a new SARS-CoV-2 variant

Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values

Estimating epidemiologic dynamics from cross-sectional viral load distributions

Virological and serological with COVID-19 in the UK: a special focus on variant detection

a whole-genome sequencing and hospital-based cohort study

Increased Transmissibility of SARS-CoV-2 Lineage B.1.1.7 by Age and Viral Load: Evidence from Danish Households

S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Covid-19: Where are we on vaccines and variants?

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

Edwards DK: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Immunity to SARS-CoV-2 variants of concern

Covid-19: The E484K mutation and the risks it poses

Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom

Fisher's exact test Male

2%) 2520 (27.4%) 3377 (27.1%)

Fisher's exact test Odds Ratio: 1.357 (95% CI 1.252 to 1.469)

Non-Invasive Ventilation 169 (9.6%) 433 (10.2%) 602 (10.0%) High Flow Oxygen

Hologic Panther 25.0 n=(385) 26.2 n=(1574) n=(1959)

Vaccine No vaccine

CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay Mechanical Ventilation 3 (17.6%) 362 (8.5%) 365 (8.6%) Non

Fisher's exact test Odds Ratio

CI: confidence interval; ICU: Intensive Care Unit; IMU: Intermediate Care Unit; ECMO: extracorporeal membrane oxygenation

J o u r n a l P r e -p r o o f